Brown, Lisle/Cummings, Inc. Acadia Pharmaceuticals Inc Transaction History
Brown, Lisle/Cummings, Inc.
- $329 Billion
- Q3 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 250 shares of ACAD stock, worth $4,092. This represents 0.0% of its overall portfolio holdings.
Number of Shares
250
Previous 250
-0.0%
Holding current value
$4,092
Previous $4.06 Million
5.37%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ACAD
# of Institutions
280Shares Held
156MCall Options Held
901KPut Options Held
314K-
Baker Bros. Advisors LP New York, NY42.9MShares$702 Million7.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.8MShares$227 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY13.7MShares$224 Million3.36% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$197 Million0.0% of portfolio
-
State Street Corp Boston, MA5.97MShares$97.8 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $2.65B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...